DocumentsDate added
RESEARCH ARTICLE
Xiao-Mei Chen,Qing Wang, Rui-Kun He, Yu-Tao Li,Xiao-Yun Chen, Hiroshi Kurihara, Rong-Rong He, Yi-Fang Li*
Institute of Traditional Chinese Medicine and Natural Products, Jinan University,Guangzhou 510632, Guangdong, China
Address reprint requests to
*Yi-Fang Li, PhD, Institute of Traditional Chinese Medicine and Natural Products,Jinan University, Guangzhou 510632,Guangdong, China
Article citation: Chen XM, Wang Q, He RK, Li YT, Chen XY, Kurihara H, He RR,Li YF. Immunomodulating effects of bleomycin and its derivatives, peplomycin and liblomycin on murine antitumour effector cells. J Pharm Biomed Sci 2016;06(05):304–310.Available at www.jpbms.info
ABSTRACT
We investigated the immunomodulating effects of bleomycin and its derivatives, peplomycin and liblomycin on natural killer (NK) cells and lymphokine-activated killer (LAK) precursor cells from the spleens of C57BL/6 mice. Results showed that bleomycin and peplomycin can increase in vitro NK and LAK precursor cell activities both per spleen and per unit number (1 × 106 ) of the spleen cells as compared with normal mice from day 1 to 9,while the number of spleen cells did not increase. Meanwhile, a single administration of liblomycin caused a decrease in the number of spleen cells and the activity of LAK precursor cells per mouse spleen from day 1 and they recovered to normal levels by day 9.
NK activity, which was also suppressed by liblomycin, recovered slowly but failed to reach the complete restoration by day 9. Liblomycin showed no effect on LAK precursor cell activity per unit number of spleen cells. Further study showed that these immunomodulating effects of bleomycin and its derivatives are apparently at least partially mediated by the endogenous cytokine release.
KEYWORDS bleomycin, peplomycin, liblomycin, natural killer cell, lymphokine-activated killer precursor cell, cytokine
References:
1.Cragg GM, Kingston DGI, Newman DJ. Anticancer agents from natural products, 2nd ed., Boca Raton: CRC Press LLC;2005.
2.Abdul Hamied TA, Parker D, Turk JL. Potentiation of release of interleukin-2 by bleomycin. Immunopharmacology. 1986;12(2):127–134.
3.Hillel AT, Samad I, Ma G, Ding D, Sadtler K, Powell JD, et al. Dysregulated macrophages are present in bleomycin-induced murine laryngotracheal stenosis. Otolaryngol Head Neck Surg.2015;153(2):244–250.
4.Xu ZY, Hosokawa M, Morikawa K, Hatakeyama M, Kobayashi H.Overcoming suppression of antitumor immune reactivity in tumor-bearing rats by treatment with bleomycin. Cancer Res.1988;8(23):6658–6663.
5.Williamson JD, Sadofsky LR, Hart SP. The pathogenesis of bleomycin-induced lung injury in animals and its applicability to human idiopathic pulmonary fibrosis. Exp Lung Res. 2015;41(2):57–73.
6.Takita T, Ogino T. Peplomycin and liblomycin, a new analogues of bleomycin. Biomed Pharmacother. 1987;41(5):219–226.
7.Takahashi K, Ekimoto H, Minamide S, Nishikawa K, Kuramochi H, Motegi A, et al. Liblomycin, a new analogue of bleomycin. Cancer Treat Rev. 1987;14(3–4):169–177.
8.Micallef M, Hosokawa M, Shibata T, Nakane A, Yang ZB,Minagawa T, et al. Immunoregulatory cytokine release in rat spleen cell cultures after treatment with bleomycin and its analogues in vivo. Cancer Immunol Immunother. 1991;33(1):33–38.
9.Ryzhkov VK, Zeidlits VN, Tikhonov KB. Use of protamine sulfate as a vasodilator in liver and spleen angiography. Vestn Rentgenol Radiol. 1977;(6):41–45.
10.Dresp J, Schmid E, Bauchinger M. The cytogenetic effect of bleomycin on human peripheral lymphocytes in vitro and in vivo. Mutat Res. 1978;56(3):341–353.
11.Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG,Wells WA, Winter JN, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin’s lymphoma. N Engl J Med.2012;366:399–408.
12.Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ.Treatment of disseminated germ-cell tumors with cisplatin,bleomycin, and either vinblastine or etoposide. N Engl J Med. 1987;316:1435–1440.
13.Bugaut H, Bruchard M, Berger H, Derangère V, Odoul L, Euvrard R, et al. Bleomycin exerts ambivalent antitumor immune effect by triggering both immunogenic cell death and proliferation of regulatory T cells. PLoS One. 2013;8(6):e65181.
14.Yoshida T, Ogawa M, Ota K, Yoshida Y, Wakui A, Oguro M, et al. Phase II study of NK313 in malignant lymphomas: an NK313 malignant lymphoma study group trial. Cancer Chemother Pharmacol. 1993;31(6):445–448.
15.Lazo JS, Braun ID, Labaree DC, Schisselbauer JC, Meandzija B, Newman RA, et al. Characteristics of bleomycin-resistant phenotypes of human cell sublines and circumvention of bleomycin resistance by liblomycin. Cancer Res. 1989;49(1):185–190.
16.Chen HY, Zheng CY, Zou GL, Xie DX, Gong JP. Peplomycin induces G1-phase specific apoptosis in liver carcinoma cell line Bel-7402 involving G2-phase arrest. Acta Pharmacol Sin.2004;25:1698–1704.
17.Fujimura T, Kambayashi Y, Furudate S, Kakizaki A, Haga T, Hashimoto A, et al. Immunomodulatory effects of peplomycin on immunosuppressive and cytotoxic cells in the lesional skin of cutaneous squamous cell carcinoma. Dermatology. 2015;230(3):250–255.
18.Schwartz HS, Grindey GB. Adriamycin and daunorubicin: a comparison of antitumor activities and tissue uptake in mice following immunosuppression. Cancer Res. 1973;33(8):1837–1844.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: None.
Acknowledgment: The authors gratefully acknowledge the PhD, Masuo Hosokawa for supporting their work.
Competing interest / Conflict of interest:
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the
official policy or position of the Department of Defense.
RESEARCH ARTICLE
Mustafa Abdelgadir Khandgawi Ibrahim*,Adel Nasr Morsi,Liza Hamdi Mohamed
Department of Chemical Pathology, Faculty of Medical Laboratory Sciences, University of Khartoum, Sudan
Address reprint requests to
*Mustafa Abdelgadir Khandgawi Ibrahim,
Department of Chemical Pathology,Faculty of Medical Laboratory Sciences, Sudan, Khartoum
Article citation: Ibrahim MAK, Morsi AN, Mohamed, LH. Lipid profiles in Sudanese women with polycystic ovary syndrome. J Pharm Biomed Sci 2016;06(05):301–303.Available at www.jpbms.info
ABSTRACT
Background Polycystic ovary syndrome (PCOS) has been one of the important public health problems in Sudan, which leads to medical consequences and ends up in sterility.
Methods This study includes 40 PCOS women with age ranged between 16 and 40 years were selected based on Rotterdam criteria 2003 and 40 ovulatory normal non-PCOs, healthy and age-matched women as control. The lipid profiles (total cholesterol, LDL-C, HDL-C and triglyceride [TG]) were measured by an enzymatic colorimetric method using biosystem reagents. The data management and analysis were done with SPSS version 22.
Results There was no significant difference between the two groups in terms of age and body mass index except TG in PCOS ladies with BMI more than 25 was significantly higher in comparison with non-PCOs.
Conclusion This study does not guide the belief that PCOS affects serum lipid ranges, besides in the term of TG in PCOS girls with BMI >25. It is far advised to do this study in ladies with PCOS sufferers from insulin resistance.
KEYWORDS lipid profiles, PCOS, Sudanese women
References:
1.Iuhas C, Costin N, Mihu D. Lipid parameters in patients with polycystic ovary syndrome. Appl Med Informatics. 2012;31(4):27–32.
2.Allahbadia GN, Merchant R. Polycystic ovary syndrome and impact on health. Middle East Fertil Soc J. 2011;16(1):19–37.
3.Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R. Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Disord. 2002;26(7):883–96.
4.Swetha N, Vyshnavi R, Modagan P, Rajagopalan B. A correlative study of biochemical parameters in polycystic ovarian syndrome. Int J Biol Med Res. 2013;4:3148–54.
5.Iuhas CI, Costin N, Mihu D. Lipid parameters in patients with polycystic ovary syndrome. Appl Med Inform Origin Res.2012;31:27–32.
6.Rizzo M, Berneis K, Carmina E, Rini GB. How should we manage atherogenic dyslipidemia in women with polycystic ovary syndrome? Am J Obstet Gynecol. 2008;198:28–5.
7.Valkenburg O, Steegers-Theunissen RP, Smedts HP, Dallinga-Thie GM, Fauser BC, Westerveld EH, et al. A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case–control study. J Clin Endocrinol Metab. 2008;93:470–6.
8.Amini L, Sadeghi MR, Oskuie F, Kamali K, Maleki H. Lipid profile in women with polycystic ovary syndrome. Crescent J Med Biol Sci. 2014;1(4):147–50.
9.Bickerton AS, Clark N, Meeking D, Shaw KM, Crook M, Lumb P,et al. Cardiovascular risk in women with polycystic ovarian syndrome (PCOS). J Clin Pathol. 2005;58:151–4.
10.Swetha N, Vyshnavi R, Modagan P, Rajagopalan B. A correlative study of biochemical parameters in olycystic ovarian syndrome. Int J Biol Med Res. 2013;4:3148–54.
11.Latha M, Bhaskar MV, Sharma SSB, Sumapreethi A. Evaluation of dyslipidemia and oxidative stress in patients with polycystic ovarian syndrome. J Evol Med Dent Sci. 2012;1(5):769–775.
12.Shoaib O, Mustafa S, Nourein I. Serum lipid profile of polycystic ovary syndrome in Sudanese women. Int J Med Sci Public Heal [Internet]. 2015;4(11):1.
13.Silfen ME, Denburg MR, Manibo AM, Lobo RA, Jaffe R, Ferin M,et al. Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents. J Clin Endocrinol Metab. 2003;88:4682–8.
14.Savic S, Zarkovic M, Ciric M, Beleslin B, Drezgic M, Trbojevic B.Lipid profile in normal weight and obese women with polycystic ovary syndrome. Endocr Abstracts. 2006;11:341.
15.Bachceci M, aydemir M, Tuzcu A. Effects of oral fat and glucose tolerance test on serum lipid profile, apolipoprotein and CRP concentration, and insulin resistance in patients with polycystic ovary syndrome. Fertil Steril. 2007;87:1363–8.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: None.
Acknowledgments: The authors are thankful to the respected Prof. Mohamed Tageldin Ibrahim Omer and Dr. Omer Balla Ibrahim for guiding them in statistical analysis.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the study.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Review article
Supriya S. Shidhaye,Bhagyashri Surendra Parab*,Ruchi Singh
Department of Pharmaceutics, Vivekanand Education Society’s College of Pharmacy,
Chembur, Mumbai, India
Address reprint requests to
*Ms. Bhgayashri Surendra Parab,
3/304, Indraprastha Bldg., Opp. Jai Hind Talkies, Lalbaug, Mumbai, 400012, India
Article citation: Shidhaye SS, Parab BS,Singh R. Current trends in biosimilars. J Pharm Biomed Sci 2016;06(05):286–292.Available at www.jpbms.info
ABSTRACT
Recombinant technology has brought a wide availability of the treatment options for many life-threatening diseases. Consistent with the great inventions in the area of biotechnology, biopharmaceuticals have become the fastest growing area of the pharmaceutical industry.
The recent expiration of many innovator biopharmaceutical products has triggered the development of alternate versions of originators biologic drugs. Unlike generic drugs, these new biological products are not the identical copies of innovator products. Thus, these alternate versions are referred to as ‘follow-on biologics’ or ‘biosimilar drugs’. Slight changes in starting materials or modification in the manufacturing processes have significant impact on the final structure of the biologic molecule. Thus, the exact structure of the originator’s biologic molecule cannot be duplicated. This makes these biosimilars very unique molecules necessitating the need for elaborate characterisation and consistent pharmacovigilance.
KEYWORDS recombinant technology, biosimilars, biopharmaceutical products
REFERENCES
1.Schellekens H. Biosimilar therapeutics: what do we need to consider? NDT Plus. 2009;2:i27–i36.
2.Mishra M. Biosimilars: current perspectives and future implications. Indian J Pharmacol. 2012;44(1):12–14.
3.Biosimilar medicines. London: European Medicines Agency. 2016. Available at: www.ema.europa.eu
4.Biosimilars. Silver Spring, MD: U.S. Food and Drug Administration.2016. Available at: www.fda.gov
5.Evaluation of Biosimilars. Woden: Therapeutic Goods Administration,Department of Health and Ageing, Australian Government. 2016. Available at: www.tga.gov.au
6.Singh B, Saluja SV. Biosimilars: an overview. Biosimilars. 2011;1:1–11, Dovepress.
7.Hinderer W. Biogeneric drugs. In: Kayser O, Muller RH, (eds):Pharmaceutical biotechnology, drug discovery and clinical applications. !!HYPERLINK “http://www.pharmatechbd.blogspot.com/” Pharmatech; 2013. pp. 119–144.
8.Lipp R, Pungor E. Formulation of biotech products. In: Kayser O,Müller RH (eds). Pharmaceutical biotechnology: drug discovery and clinical applications. Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA. 2004. pp. 173–185.
9.Resnik DB. Patents in pharmaceutical industry: legal and ethical issues. In: Kayser O, Müller RH (eds). Pharmaceutical biotechnology:drug discovery and clinical applications. Weinheim: Wiley- VCH Verlag GmbH & Co. KGaA. 2004. pp. 187–199.
10.Walsh G. Drug Approval in the European Union and the United States. In: Kayser O, Müller RH (eds). Pharmaceutical biotechnology:drug discovery and clinical applications. Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA. 2004. pp. 201–210.
11.Singh BD. Animal tissue culture and hybridoma technology.In: Biotechnology: expanding horizons. New Delhi: Kalyani Publishers. 2008. pp. 207–233.
12.Watson JD, Gilman M. Recombinant DNA in medicine and industry, 2nd ed., In: Recombinant DNA. New York: Scientific American Books. 1992. pp. 462–468.
13.Abrams JS, Chretien I, Lee FD, Pearce MK. Monoclonal antibodies against human interleukin-4 and hybridomas producing the same. USA: Schering Biotech Corp. European Patent Register.
14.Rgen JJ, Brange V, Havelund S. Insulin analouges. European Patent Register.
15.Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars.Ann Oncol. 2008;19:411–419.
16.Rane SS, Diwan N, Narayan O, Mody R. Developing robust approaches to the effective characterization of biosimilars. Available at: www.pharmafocusasia.com
17.World’s first biosimilar antibody approved in India, July 23, 2012.Available at: www.biosimilarnews.com
18.Biosimilar medicinal products: what do you need to know about? A Consensus Information Document, European Commission.
19.Wiecek A, Mikhail A. European regulatory guidelines for biosimilars. Nephrol Dial Transplant. 2006;21(5):v17–v20.
20.Developing biosimilars in emerging markets: regulatory and clinical considerations. White paper ppdi.com. 2013.
Original article
Amit Agrawal*,Sipra Lenka,Pratima Mishra
Department of Obstetric and Gynaecology, Hi-Tech Medical College and Hospital, Bhubaneswar, Odisha, India
Address reprint requests to
*Dr. Amit Agrawal,
Department of Obstetrics and Gynaecology, Hi-Tech Medical College and Hospital,Bhubaneshwar, Orissa, India
Article citation: Agrawal A, Lenka S,Mishra P. Study of age, parity and contraceptive use as risk factors in cervical carcinoma. J Pharm Biomed Sci 2016;06(05):293–294.Available at www.jpbms.info
Abstract
Background Cervix is one of the most common genital malignancy leading to increased mortality in women, Early diagnosis by different screening modalities can reduce the mortality. Identification of high risk group and putting them for screening can reduce disease burden.
Materials and Methods The study of age, parity and contraceptive use as risk factors in cervical carcinoma were carried out from patients attending the O & G OPD in Hi-Tech Medical College and Hospital, Bhubaneswar, Odisha, India during the period from January 2014 to January 2015.
Results The study was conducted on 100 cases in Hi-Tech Medical College and Hospital with features of unhealthy cervix, and the results were analysed.
Conclusion In this study, different risk factors like age of the patient, parity and the use of contraceptive methods have been studied and analysed.
KEYWORDS unhealthy cervix, parity, contraception in CIN
REFERENCES
1.Kushtagi P, Fernandez P. Significance of persistent inflammatory, cervical smears in sexually active women of reproductive age. J Obstet Gynaecol India. 2002;52(1):124–6.
2.Maiman M, Fruchter RG, Sedlis A, Feldman J, Chen P, Burk RD,et al. Prevalence, risk factors, and accuracy of cytologic screening for cervical intraepithelial neoplasia in women with the human immunodeficiency virus. Gynaecol Oncol. 1998;68(3):233–9.
3.Schmauz R, Okong P, de Villiers EM, Dennin R, Brade L, Lwanga SK, et al. Multiple infections in cases of cervical cancer from a high-incidence area in tropical Africa. Int J Cancer. 1989;43:805–9.
4.Vaidya A. Comparison of Pap test among high and non-high risk female. Kathmandu Univ Med J. 2003;1(1):8–13.
5.Sukhpreet LS, Nayana AD, Murari SN. Comparison of colposcopy and pap smear: sensitivity, specificity and predictive values. BHJ.2000;42:4.
6.Verreault R, Chu J, Mandelson M, Shy K. A case–control study of diet and invasive cervical cancer. Int J Cancer. 1989;43:1050–4.
7.Yarandi F, Izadi MN, Mirashrafi F, Eftekhar Z. Colposcopic and histologic findings in women with a cytologic diagnosis of atypical squamous cells of undetermined significance. Aust N Z J Obstet Gynaecol. 2004;44(6):514–6.
ORIGINAL ARTICLE
Zhang Bei-Bei1,He Jin-Lian2,Bei Yu2,Zhang You-Ying1,Huang Ya-Dong1,2,Xiang Qi1,2*
1 College of Pharmacy, Jinan University, Guangzhou 510632, P.R. China
2 Institute of Biomedicine and Guangdong Provincial Key Laboratory of Bioengineering Medicine, Jinan University, Guangzhou 510632, P.R. China
Address reprint requests to
* Xiang Qi, Associate Professor, College of Pharmacy, Jinan University, Guangzhou 510632, P.R. China
Article citation: Bei-Bei Z, Jin-Lian H, Yu B,You-Ying Z, Ya-Dong H, Qi X. Safety evaluation of GP-EGF lyophilised powder.J Pharm Biomed Sci 2016;06(05):295–300.Available at www.jpbms.info
ABSTRACT
To clarify the safe risks related to the use of GP-EGF lyophilised powder (GELP), acute toxicity test, dermal allergy test, dermal irritation test, and subchronic toxicological test were evaluated according to the guideline for hygienic standard for cosmetics (2007). In acute toxicity tests using guinea pigs, there was no treatment-related mortality, clinical signs of toxicity, body weight changes and gross findings at a dose level of 2,000 mg·kg−1·d−1. Similarly, dermal allergy test using guinea pigs and dermal irritation test using rabbits revealed no mortality, clinical signs of toxicity and a corrosion reaction on the skin. In the subchronic study, no death or clinical signs, or abnormal haematological, biochemical and histopathological changes were found in rats after receiving, by the concentration in
56 mg·mL−1·d−1, 112 mg·mL−1·d−1 of GELP for 90 days. Our findings indicated that GELP is relatively safe since it did not induce an acute toxicity test, dermal allergy test, dermal irritation test and subchronic toxicological test.
KEYWORDS EGF, GP-EGF lyophilised powder (GELP), acute toxicity test, dermal allergy test, dermal irritation test, subchronic toxicological test.
REFERENCES
1.Hashimoto K. Regulation of keratinocyte function by growth factors. J Dermatol Sci. 2000;24(1):S46–S50.
2.Hashimoto K, Higashiyama S, Asada H, Hashimura E, Kobayashi T, Sudo K, et al. Heparin-binding epidermal growth factor-like growth factor is an autocrine growth factor for human keratinocytes.J Biol Chem. 1994;269(31):20060–6.
3.Feldser D, Agani F, Iyer NV, Pak B, Ferreira G, Semenza GL. Reciprocal positive regulation of hypoxia-inducible factor 1α and insulin-like growth factor 2. Cancer Res. 1999;59(16):3915–8.
4.Barr S, Thomson S, Buck E, Russo S, Petti F, Sujka-Kwok I, et al. Bypassing cellular EGF receptor dependence through epithelial-to- mesenchymal-like transitions. Clin Exp Metastasis. 2008;25(6):685–93.
5.Bhat FA, Sharmila G, Balakrishnan S, Arunkumar R, Elumalai P, Suganya S, et al. Quercetin reverses EGF-induced epithelial to mesenchymal transition and invasiveness in prostate cancer (PC-3) cell line via EGFR/PI3K/Akt pathway. J Nutr Biochem.2014;25(11):1132–9.
6.Huber MA, Kraut N, Beug H. Molecular requirements for epithelial–mesenchymal transition during tumor progression. Curr Opin Cell Biol. 2005;17(5):548–58.
7.Cheng JC, Klausen C, Leung PC. Hypoxia-inducible factor 1 alpha mediates epidermal growth factor-induced down-regulation of E-cadherin expression and cell invasion in human ovarian cancer cells. Cancer Lett. 2013;329(2):197–206.
8.Cheng JC, Auersperg N, Leung PC. EGF-induced EMT and invasiveness in serous borderline ovarian tumor cells: a possible step in the transition to low-grade serous carcinoma cells? PLoS ONE. 2012;7(3):e34071.
9.Ficheux AS, Chevillotte G, Wesolek N, Morisset T, Dornic N, Bernard A, et al. Consumption of cosmetic products by the French population second part: amount data. Food Chem Toxicol. 2016;90:130–41.
10.Ma’or Z, Halicz L, Portugal-Cohen M, Russo MZ, Robino F,Vanhaecke T, et al. Safety evaluation of traces of nickel and chrome in cosmetics: the case of Dead Sea mud. Regul Toxicol Pharmacol. 2015;73(3):797–801.
11.Hrabchak C, Rouleau J, Moss I, Woodhouse K, Akens M, Bellingham C, et al. Assessment of biocompatibility and initial evaluation of genipin cross-linked elastin-like polypeptides in the treatment of an osteochondral knee defect in rabbits. Acta biomater. 2010;6(6):2108–15.
12.Viswanath L, Reddy KBKM, Vidyasagar M, Koteshwar R, Shenoy AM, Thimmaiah N, et al. A phase IIb, 4 arm open-label, randomized trial, to assess the safety and efficacy of concurrent hR3 monoclonal antibody against EGF-receptor with chemoradiation therapy or with radiation therapy in patients with advanced (stage III–IVa), inoperable head and neck cancer. Int J Rad Oncol Biol Phys. 2009;75(3):S15–S6.
13.Mancebo A, Casacó A, González B, Ledón N, Sorlozabal J,León A, et al. Repeated dose intramuscular injection of the CIMAvax-EGF vaccine in Sprague Dawley rats induces local and systemic toxicity. Vaccine. 2012;30(22):3329–38.
14.Wang Y, Liu P, Qiu L, Sun Y, Zhu M, Gu L, et al. Toxicity and therapy of cisplatin-loaded EGF modified mPEG-PLGA-PLL nanoparticles for SKOV3 cancer in mice. Biomaterials. 2013;34(16):4068–77.
15.Ko H, Kim JM, Kim SJ, Shim SH, Ha CH, Chang HI. Induction of apoptosis by genipin inhibits cell proliferation in AGS human gastric cancer cells via Egr1/p21 signaling pathway. Bioorg Med Chem Lett. 2015;25(19):4191–6.
16.Fiamingo A, Campana-Filho SP. Structure, morphology and properties of genipin-crosslinked carboxymethylchitosan porous membranes. Carbohydr Polym. 2016;143:155–63.
17.Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell.2000;103(2):211–25.
18.Cañón-Beltrán K, Cajas Y, Garcia-Garcia R, Lorenzo P, Carrera R, Rebollar P, et al. Effect of epidermal growth factor on nuclear and cytoplasmic in vitro maturation of guinea pig oocytes. Anim Reprod. 2015;12(3):793.
19.Madhukar BV, Brewster DW, Matsumura F. Effects of in vivo-administered 2,3,7,8-tetrachlorodibenzo-p-dioxin on receptor binding of epidermal growth factor in the hepatic plasma membrane of rat, guinea pig, mouse, and hamster. Proc Natl Acad Sci U S A. 1984;81(23):7407–11.
20.Kim JS, McKinnis VS, Nawrocki A, White SR. Stimulation of migration and wound repair of guinea-pig airway epithelial cells in response to epidermal growth factor. Am J Respir Cell Mol Biol. 1998;18(1):66–74.
21.Mondain M, Ryan A. Epidermal growth factor and basic fibroblast growth factor are induced in guinea-pig tympanic membrane following traumatic perforation. Acta Otolaryngol. 1995;115(1): 50–4.
22.Koo HJ, Lim KH, Jung HJ, Park EH. Anti-inflammatory evaluation of gardenia extract, geniposide and genipin. J Ethnopharmacol. 2006;103(3):496–500.
23.Wang M, Corpuz CC. Effects of scleral cross-linking using genipin on the process of form-deprivation myopia in the guinea pig: a randomized controlled experimental study. BMC Ophthalmol.2015;15(1):89.
24.Moore M, Adams A. Calcification resistance, biostability, and low immunogenic potential of porcine heart valves modified by dye-mediated photooxidation. J Biomed Mater Res.2001;56(1):24–30.
25.Raymond G, Jumblatt M, Bartels S, Neufeld A. Rabbit corneal endothelial cells in vitro: effects of EGF. Invest Ophthalmol Vis Sci. 1986;27(4):474–9.
26.Lee JH, Baek HR, Lee KM, Lee DY, Lee AY. Enhanced osteoinductivity of recombinant human bone morphogenetic protein-2 in combination with epidermal growth factor in a rabbit tibial defect model. Growth Factors. 2015;33(1):31–9.
27.Hou Y, Tsai SY, Lai P, Chen Y, Chao P. Metabolism and pharmacokinetics of genipin and geniposide in rats. Food Chem Toxicol. 2008;46(8):2764–9.
28.Nam KN, Choi YS, Jung HJ, Park GH, Park JM, Moon SK, et al. Genipin inhibits the inflammatory response of rat brain microglial cells. Int Immunopharmacol. 2010;10(4):493–9.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: None.
Acknowledgments: The authors would like to thank their colleague Su Wan who works in the institute of Biomedicine and Guangdong Provincial Key Laboratory of Bioengineering Medicine in Jinan University for the supplement of GELP and EGF.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the study.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.